Clinical proteomics: Translating benchside promise into bedside reality

被引：392

作者：

Petricoin, EF ^{[1
]}

Zoon, KC

Kohn, EC

Barrett, JC

Liotta, LA

机构：

[1] US FDA, FDA NCI Clin Proteom Program, Div Therapeut Prot, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA

[2] US FDA, Off Director, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA

[3] NCI, Ctr Canc Res, NIH, FDA NCI Clin Proteom Program,Lab Pathol, Bethesda, MD 20892 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2002年 / 1卷 / 09期

关键词：

D O I：

10.1038/nrd891

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The ultimate goal of proteomics is to characterize the information flow through protein networks. This information can be a cause, or a consequence, of disease processes. Clinical proteomics is an exciting new subdiscipline of proteomics that involves the application of proteomic technologies at the bedside, and cancer, in particular, is a model disease for studying such applications. Here, we describe proteomic technologies that are being developed to detect cancer earlier, to discover the next generation of targets and imaging biomarkers, and finally to tailor the therapy to the patient.

引用

页码：683 / 695

页数：13

共 92 条

[41] Molecular addresses in blood vessels as targets for therapy [J].